http://www.onemedplace.com/blog/wp-content/uploads/2009/09/ovariancancer.jpg
The U.S. Food and Drug Administration has approved a blood test to detect ovarian cancer and help physicians decide what kind of surgery should be done and by whom.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/10/access2.jpg
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company's pipeline.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2009/11/clinicaltrial.jpg
CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced,...
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2010/01/vials1.jpg
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2010/04/pills2.jpg
An experimental drug from Nektar Therapeutics was able to shrink tumors and reduce a cancer biomarker in women with advanced ovarian cancer in a mid-stage study.
View Articlehttp://www.onemedplace.com/blog/wp-content/uploads/2010/05/test_tubes.jpg
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
View ArticleOneMedForum Recap: Del Mar Pharmaceuticals
Delmar Pharmaceuticals (DMPI) is a clinical and early stage Oncologyl Company focused on developing and commercializing leading anti-cancer therapies in high impact orphan oncological indications...
View Article
